Sugi Predict

Sugi Predict / Compounds / SCHEMBL1004635

SCHEMBL1004635

SCHEMBL1004635

N=C(N)NCCC[C@@H](N)C(=O)NCCC[C]=O

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DPP7 Q9UHL4 2/20 0.47
▸ GNAI3 P08754 1/20 0.42
▸ GNAO1 P09471 1/20 0.42
▸ GNAI1 P63096 1/20 0.42
▸ RRM1 P23921 1/20 0.41
▸ NOS1 P29475 1/20 0.38
▸ NPY4R P50391 8/20 0.38
▸ NPY1R P25929 5/20 0.38
▸ NPY2R P49146 4/20 0.38
▸ NPY5R Q15761 4/20 0.38
▸ OTC P00480 1/20 0.34
▸ NOD1 Q9Y239 1/20 0.34
▸ ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521224 0.94 DPP7 (0.49) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL1521786 0.94 DPP7 (0.49) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL1521379 0.94 DPP7 (0.47) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL1521162 0.89 NPY4R (0.47) DPP7GNAI3GNAO1GNAI1NPY4R
SCHEMBL1521341 0.88 NPY4R (0.48) DPP7GNAI3GNAO1GNAI1NPY4R
SCHEMBL23610947 0.87 DPP7 (0.61) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL23626315 0.87 DPP7 (0.61) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL1521349 0.86 DPP7 (0.49) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL6368171 0.86 DPP7 (0.49) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL6368164 0.86 DPP7 (0.49) DPP7GNAI3GNAO1GNAI1RRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-01 — — US claimed
US-20110118172-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 — — US claimed
EP-2314609-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-04-27 — — EP claimed
JP-4653840-B2 — — 2011-03-16 — — JP claimed
US-20110059888-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-10 — — US claimed
EP-2277900-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-01-26 — — EP claimed
US-20090298765-A1 Metastin derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-03 — — US claimed
EP-2113513-A2 Metastin derivatives and use thereof Takeda Pharmaceutical Company Limited (JP) 2009-11-04 — — EP claimed
US-20090215700-A1 Metastin derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-27 — — US claimed
EP-2081955-A1 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-07-29 — — EP claimed
JP-2009520682-A — — 2009-05-28 — — JP claimed
US-20090105152-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US claimed
US-20080312155-A1 Metastin Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 — — US claimed
EP-1963362-A1 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-09-03 — — EP claimed
WO-2008050897-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 — — WO claimed
WO-2007072997-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 — — WO claimed
EP-1758932-A2 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-03-07 — — EP claimed
WO-2006001499-A2 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 — — WO claimed
EP-3210998-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2017-08-30 — — EP disclosed
WO-2006001499-A2 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215700-A1 Metastin derivatives and use thereof SHBG, GNRHR, INHA DPP7 135/4885GNAI3 149/4885GNAO1 373/4885
US-20080312155-A1 Metastin Derivatives and Use Thereof GNRHR, SHBG, MEN1 DPP7 68/4885GNAI3 377/4885GNAO1 513/4885
US-20110059888-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA DPP7 135/4885GNAI3 149/4885GNAO1 373/4885
US-20110118172-A1 METASTIN DERIVATIVE AND USE THEREOF GNRHR, SHBG, INHA DPP7 193/4885GNAI3 165/4885GNAO1 264/4885
US-20090298765-A1 Metastin derivatives and use thereof GNRHR, SHBG, MEN1 DPP7 68/4885GNAI3 377/4885GNAO1 513/4885
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF GNRHR, SHBG, LHCGR DPP7 225/4885GNAI3 224/4885GNAO1 331/4885
US-20090105152-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA DPP7 106/4885GNAI3 167/4885GNAO1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.